Brian Skorney
Stock Analyst at Baird
(4.23)
# 599
Out of 4,641 analysts
95
Total ratings
50.77%
Success rate
16.48%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Reiterates: Underperform | $215 | $319.66 | -32.74% | 4 | Sep 25, 2024 | |
| BHVN Biohaven | Maintains: Outperform | $58 → $60 | $52.65 | +13.96% | 2 | Sep 23, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $39 → $44 | $39.68 | +10.89% | 3 | Aug 8, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $157 → $180 | $116.78 | +54.14% | 4 | Aug 2, 2024 | |
| BIIB Biogen | Maintains: Outperform | $316 → $294 | $185.90 | +58.15% | 15 | Jul 29, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $170 → $200 | $128.42 | +55.74% | 8 | Jun 21, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $80 | $88.16 | -9.26% | 1 | Jun 20, 2024 | |
| LXEO Lexeo Therapeutics | Initiates: Outperform | $28 | $10.07 | +178.05% | 1 | Jun 13, 2024 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $52 → $62 | $59.61 | +4.01% | 4 | May 23, 2024 | |
| SLNO Soleno Therapeutics | Initiates: Outperform | $72 | $53.64 | +34.23% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $2 | $1.75 | +14.29% | 4 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $9.59 | +306.67% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $32 | $14.53 | +120.23% | 1 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $42.74 | +47.40% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $800 → $760 | $962.34 | -21.03% | 12 | Jun 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $474.91 | -31.57% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $14 | $8.72 | +60.55% | 3 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $90 | $13.00 | +592.31% | 5 | May 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $29.60 | -66.22% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $3.10 | +8,609.68% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $6.19 | -3.07% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $5.45 | +5,404.59% | 3 | May 7, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $220.63 | - | 2 | Nov 14, 2017 |
Amgen
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $319.66
Upside: -32.74%
Biohaven
Sep 23, 2024
Maintains: Outperform
Price Target: $58 → $60
Current: $52.65
Upside: +13.96%
Mirum Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $39 → $44
Current: $39.68
Upside: +10.89%
Neurocrine Biosciences
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $116.78
Upside: +54.14%
Biogen
Jul 29, 2024
Maintains: Outperform
Price Target: $316 → $294
Current: $185.90
Upside: +58.15%
Sarepta Therapeutics
Jun 21, 2024
Maintains: Outperform
Price Target: $170 → $200
Current: $128.42
Upside: +55.74%
Gilead Sciences
Jun 20, 2024
Maintains: Neutral
Price Target: $80
Current: $88.16
Upside: -9.26%
Lexeo Therapeutics
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $10.07
Upside: +178.05%
Crinetics Pharmaceuticals
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $59.61
Upside: +4.01%
Soleno Therapeutics
May 10, 2024
Initiates: Outperform
Price Target: $72
Current: $53.64
Upside: +34.23%
Apr 16, 2024
Downgrades: Neutral
Price Target: $20 → $2
Current: $1.75
Upside: +14.29%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $9.59
Upside: +306.67%
Feb 27, 2024
Initiates: Outperform
Price Target: $32
Current: $14.53
Upside: +120.23%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $42.74
Upside: +47.40%
Jun 28, 2023
Maintains: Neutral
Price Target: $800 → $760
Current: $962.34
Upside: -21.03%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $474.91
Upside: -31.57%
Apr 25, 2023
Maintains: Outperform
Price Target: $18 → $14
Current: $8.72
Upside: +60.55%
May 19, 2022
Maintains: Outperform
Price Target: $130 → $90
Current: $13.00
Upside: +592.31%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $29.60
Upside: -66.22%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $3.10
Upside: +8,609.68%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $6.19
Upside: -3.07%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $5.45
Upside: +5,404.59%
Nov 14, 2017
Downgrades: Neutral
Price Target: n/a
Current: $220.63
Upside: -